Media coverage about Curis (NASDAQ:CRIS) has been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Curis earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.6022467672185 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern’s rankings:
- Curis, Inc. (NASDAQ:CRIS) – Investor’s Roundup (P/E Analysis) – Nasdaq Journal (nasdaqjournal.com)
- Most Recent Figure Make This Stock Even More Attractive – Curis Inc (NASDAQ: CRIS) – Alpha Beta Stock (alphabetastock.com)
- An Eye on Data: Curis Inc (NASDAQ: CRIS) – Alpha Beta Stock (alphabetastock.com)
- Curis, Inc. (CRIS) Expected to Announce Quarterly Sales of $2.03 Million (americanbankingnews.com)
Shares of Curis (CRIS) remained flat at $$0.55 during trading on Monday. 908,200 shares of the stock traded hands, compared to its average volume of 1,502,706. The company has a market capitalization of $89.54, a P/E ratio of -1.38 and a beta of 1.56. Curis has a 52-week low of $0.48 and a 52-week high of $3.22. The company has a quick ratio of 5.15, a current ratio of 5.15 and a debt-to-equity ratio of 1.24.
Several research analysts have weighed in on CRIS shares. Guggenheim started coverage on Curis in a report on Monday, October 23rd. They set a “buy” rating and a $7.00 target price on the stock. Zacks Investment Research lowered Curis from a “hold” rating to a “sell” rating in a report on Friday, November 10th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. Curis has an average rating of “Hold” and a consensus target price of $6.50.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.thelincolnianonline.com/2018/02/19/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-curis-cris-stock-price-updated.html.
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.